Re: Thyroid incidentalomas in FDG-PET/CT: prevalence and clinical impact

Stack, Brendan C.; Bodenner, Donald; Bartel, Twyla; Boeckmann, Jacob

doi:10.1007/s00405-012-1985-8

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PET thyroid gland uptake above background levels may prompt evaluation of the thyroid. PET positivity within the thyroid gland may be either diffuse or focal 2–5 . Diffuse thyroid uptake on PET is typically reflective of thyroiditis, most commonly autoimmune thyroid disease (Hashimoto's thyroiditis), and is confirmed by thyroid function and directed antibody testing 6,7 .…”

Section: Introductionmentioning

confidence: 99%

“…PET positivity within the thyroid gland may be either diffuse or focal. [2][3][4][5] Diffuse thyroid uptake on PET is typically reflective of thyroiditis, most commonly autoimmune thyroid disease (Hashimoto's thyroiditis), and is confirmed by thyroid function and directed antibody testing. 6,7 These patients are often prescribed thyroid supplementation and returned to the care of the breast and primary care teams.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Breast and thyroid cancer: A multicenter study with Accrual to Clinical Trials Network

Peckham

Spencer

Syed

et al. 2022

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Objective: To investigate a possible link between breast and thyroid cancer.Methods: A multicenter retrospective review of patients in the electronic medical records of six Accrual to Clinical Trial (ACT) institutions with both breast cancer and thyroid carcinoma. Each center queried its data using a predefined data dictionary. Information on thyroid and breast cancer included dates of diagnosis, histology, and patient demographics.Results: A random-effects model was used. There were 4.24 million women's records screened, 44 605 with breast cancer and 11 846 with thyroid cancer. The relative risks observed at each institution ranged from 0.49 to 13.47. The combined risk ratio (RR) estimate was 1.77 (95% confidence interval: 0.50-5.18). Conclusion:There was no association between the risk of developing thyroid cancer and being a breast cancer survivor compared to no history of breast cancer, but the range of relative risks among the participating institutions was wide. Our findings warrant further study of more institutions with larger sample size. Additionally, further analysis of the significance of regional RR differences may be enlightening.

show abstract

Section: Introductionmentioning

confidence: 99%